BioCentury
ARTICLE | Politics, Policy & Law

Proposed CMS rule for CAR Ts marks progress in reimbursing new technologies

A new CMS payment rule for CAR Ts could mean better patient access

May 29, 2020 5:19 PM UTC

It’s been four years since the first CAR T cell therapies were approved and inadequate reimbursement is still a barrier to access in the U.S. A new payment rule proposed by CMS aims to change that, and its adoption could provide a road map to faster implementation of payment models for the next new technologies.

On May 11, CMS released its proposed Hospital Inpatient Prospective Payment System rule for 2021, which includes a new Medicare Severity-Diagnosis Related Group (MS-DRG) for CAR T cell therapies...